Google
BNGO 株価分析 — Bionano Genomics Inc (Healthcare >> Medical Instruments & Supplies)
BNGO に関するよくある質問
BNGOのROE（自己資本利益率）は？
Bionano Genomics IncのROEは-84.34%です。
BNGOの配当利回りは？
Bionano Genomics Incの配当利回りは0.00%です。
BNGOの品質スコア（Quality Score）は？
当社のAIはBNGOの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BNGOは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BNGOはどのセクターに属しますか？
Bionano Genomics IncはHealthcare >> Medical Instruments & Suppliesセクターに分類されます（NASDAQ市場）
BNGO AI Analysis Summary
Our AI summary for BNGO: Bionano Genomics Inc (NASDAQ), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of 0.00, ROE of -84.34%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.07
Price
-0.05
(-4.46%)
Day Change
|
|
|---|
BNGO, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 70 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.07 |
| PBV / Sector |
0.34 / 3.42
GREAT
|
| Earning Per Share | -2.63 |
| PE / Sector |
N/A / 44.60
|
| PEG or PE/Growth / Sector |
N/A / -1.27
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.19 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
54% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:43 |
| Symbol | BNGO |
| Name | BIONANO GENOMICS INC |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 11.48 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 12.85 / 16,487.91 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9540 Towne Centre Drive, San Diego, CA, United States, 92121
Phone: 858 888 7600
Website: https://bionano.com
Employees: 95
Description: Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
